Alfahmi Anwar Seraj, Alqarni Lana Abdullah, Alkhatabi Lura Abdulrahman, Alshehri Fahad S
College of Pharmacy, Umm Al-Qura University, Makkah 24382, Saudi Arabia.
Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 24382, Saudi Arabia.
Healthcare (Basel). 2025 Sep 6;13(17):2231. doi: 10.3390/healthcare13172231.
Calcitonin gene-related peptide (CGRP) inhibitors represent a novel class of medications for the prevention and treatment of migraines. Given their expanding role in migraine management, pharmacists are increasingly expected to be knowledgeable about their use. However, limited data exist regarding pharmacists' awareness and engagement with CGRP inhibitors in Saudi Arabia. To assess the knowledge, attitudes, and practices (KAP) of pharmacists in Saudi Arabia toward CGRP inhibitors for migraine management and identify areas for improvement. A cross-sectional survey was conducted from October 2024 to January 2025 among licensed pharmacists in Saudi Arabia using an online questionnaire distributed via social media platforms, pharmacy networks, and in-person outreach. The survey consisted of 26 questions across four sections: demographics, knowledge, attitudes, and practices. Descriptive statistics and regression analyses were performed to evaluate the data using SPSS version 29. A total of 419 pharmacists participated (response rate: 98.8%). Most practiced in community pharmacies (90.5%) and the Western region (48.2%). Overall, pharmacists demonstrated moderate knowledge (54.7%), attitudes (55.6%), and practices (49.9%) toward CGRP inhibitors in migraine management. While 54.7% were familiar with CGRP inhibitors, only 37.2% were aware of relevant clinical guidelines, and 32.5% recognized adverse effects such as hypertension. Regarding attitudes, 32.2% believed CGRP inhibitors were superior to conventional therapies, but over 50% expressed neutral views across key items. Practice patterns revealed limited engagement, with more than half reporting neutral responses toward patient education, interdisciplinary collaboration, and safety monitoring. The study highlights moderate awareness but suboptimal application of CGRP inhibitor knowledge among pharmacists. Notable gaps exist in guideline familiarity, patient education, and interdisciplinary collaboration. Targeted training and inclusion of CGRP inhibitors in pharmacy curricula and continuing education programs are warranted to support effective migraine management.
降钙素基因相关肽（CGRP）抑制剂是一类用于预防和治疗偏头痛的新型药物。鉴于其在偏头痛管理中日益重要的作用，人们越来越期望药剂师了解其使用方法。然而，关于沙特阿拉伯药剂师对CGRP抑制剂的认知和使用情况的数据有限。为了评估沙特阿拉伯药剂师对用于偏头痛管理的CGRP抑制剂的知识、态度和实践（KAP），并确定需要改进的领域。2024年10月至2025年1月，对沙特阿拉伯的执业药剂师进行了一项横断面调查，使用通过社交媒体平台、药房网络和亲自宣传分发的在线问卷。该调查包括四个部分的26个问题：人口统计学、知识、态度和实践。使用SPSS 29版进行描述性统计和回归分析以评估数据。共有419名药剂师参与（回复率：98.8%）。大多数在社区药房工作（90.5%），位于西部地区（48.2%）。总体而言，药剂师对偏头痛管理中CGRP抑制剂的知识（54.7%）、态度（55.6%）和实践（49.9%）表现为中等水平。虽然54.7%的人熟悉CGRP抑制剂，但只有37.2%的人了解相关临床指南，32.5%的人认识到如高血压等不良反应。在态度方面，32.2%的人认为CGRP抑制剂优于传统疗法，但超过50%的人在关键项目上表达了中立观点。实践模式显示参与度有限，超过一半的人对患者教育、跨学科协作和安全监测给出了中立回复。该研究强调药剂师对CGRP抑制剂的认知中等，但知识应用欠佳。在指南熟悉程度、患者教育和跨学科协作方面存在明显差距。有必要进行有针对性的培训，并将CGRP抑制剂纳入药学课程和继续教育项目，以支持有效的偏头痛管理。
